A COST-CALCULATOR MODEL TO ESTIMATE THE ECONOMIC IMPACT OF OBINUTUZUMAB FOR THE TREATMENT OF LUPUS NEPHRITIS IN ITALY
Author(s)
Camilla Porta, MSc1, Tatiana Simion, MSc1, Paolo Di Procolo, PhD2, Andrea D'ambrosio, MSc2, Mariele Gatto, Prof.3.
1AdRes HE&OR, Turin, Italy, 2Roche SpA, Monza, Italy, 3Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
1AdRes HE&OR, Turin, Italy, 2Roche SpA, Monza, Italy, 3Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
OBJECTIVES: Lupus nephritis (LN) is a common and severe manifestation of systemic lupus erythematosus associated with substantial clinical and economic burden. Despite recent advances in immunosuppressive therapy for LN, there remains a need for effective treatments that can offer durable remission while reducing treatment burden on patients. Obinutuzumab (OBI), administered intravenously, combines demonstrated clinical benefit in LN with a convenient dosing regimen. This study aimed to estimate per-patient costs of OBI compared with reimbursed advanced therapies for adult patients with LN in Italy.
METHODS: A cost-calculator model was developed to compare per-patient costs of OBI with voclosporin (VOC), intravenous belimumab (BEL IV), and subcutaneous belimumab (BEL SC) over 3 years. Analyses were conducted from the Italian National Health Service (NHS) perspective, including drug acquisition, administration, and adverse event costs, and from the societal perspective, additionally including productivity loss and transportation costs. Dosing and administration schedules were based on product information. Unit costs were derived from Italian sources, with drug costs valued using maximum hospital tender price. The model assumed treatment continuation over the time horizon.
RESULTS: From the NHS perspective, OBI had the lowest 3-year cumulative cost per patient (€13,800). Comparator costs ranged from €18,751 for BEL IV to €24,079 for VOC, with BEL SC at €19,343. Savings with OBI were €4,951 versus BEL IV, €5,543 versus BEL SC, and €10,279 versus VOC. From the societal perspective, OBI remained the least costly (€15,042), compared with BEL SC (€22,470), BEL IV (€22,839), and VOC (€25,685), with savings of €7,428, €7,797, and €10,643, respectively. Cost differences were mainly driven by lower drug acquisition, administration-related, productivity, and transportation costs.
CONCLUSIONS: Over 3 years, OBI was the least costly advanced therapy for adult LN patients in Italy from both the NHS and societal perspectives. These findings can support budget planning and resource allocation.
METHODS: A cost-calculator model was developed to compare per-patient costs of OBI with voclosporin (VOC), intravenous belimumab (BEL IV), and subcutaneous belimumab (BEL SC) over 3 years. Analyses were conducted from the Italian National Health Service (NHS) perspective, including drug acquisition, administration, and adverse event costs, and from the societal perspective, additionally including productivity loss and transportation costs. Dosing and administration schedules were based on product information. Unit costs were derived from Italian sources, with drug costs valued using maximum hospital tender price. The model assumed treatment continuation over the time horizon.
RESULTS: From the NHS perspective, OBI had the lowest 3-year cumulative cost per patient (€13,800). Comparator costs ranged from €18,751 for BEL IV to €24,079 for VOC, with BEL SC at €19,343. Savings with OBI were €4,951 versus BEL IV, €5,543 versus BEL SC, and €10,279 versus VOC. From the societal perspective, OBI remained the least costly (€15,042), compared with BEL SC (€22,470), BEL IV (€22,839), and VOC (€25,685), with savings of €7,428, €7,797, and €10,643, respectively. Cost differences were mainly driven by lower drug acquisition, administration-related, productivity, and transportation costs.
CONCLUSIONS: Over 3 years, OBI was the least costly advanced therapy for adult LN patients in Italy from both the NHS and societal perspectives. These findings can support budget planning and resource allocation.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE273
Topic
Economic Evaluation
Disease
Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)